Literature DB >> 34253428

Dihydroberberine, an isoquinoline alkaloid, exhibits protective effect against dextran sulfate sodium-induced ulcerative colitis in mice.

Cailan Li1, Na Dong2, Bowen Wu2, Zhimi Mo2, Jianhui Xie3, Qiang Lu4.   

Abstract

BACKGROUND: As a chronic inflammatory disease, ulcerative colitis (UC) is relevant to a rising risk of colorectal cancer. Dihydroberberine (DHBB), a natural occurring isoquinoline alkaloid with various bioactivities, was found in many plants including Coptis chinensis Franch. (Ranunculaceae), Phellodendron chinense Schneid. (Rutaceae), and Chelidonium majus L. (Papaveraceae). However, its protective effect on UC is sparsely dissected out.
PURPOSE: To explore the protective role and underlying mechanism of DHBB on a model of colitis.
METHODS: Acute colitis model was established by gavage with 3% dextran sulfate sodium (DSS) for 8 days. Influence of DHBB on DSS-induced clinical symptoms and disease activity index (DAI) was monitored and analyzed. Pathological injury of colon tissues was examined by hematoxylin-eosin and Alcian blue staining. The expression of intestinal mucosal barrier function proteins, immune-inflammation related biomarkers and signal pathway key targets were determined by ELISA kit, Western blot, immunohistochemistry and qRT-PCR.
RESULTS: DHBB treatment effectively alleviated DSS-induced UC by relieving clinical manifestations, DAI scores and pathological damage, which exerted similar beneficial effect to azathioprine (AZA), and better than berberine (BBR). In addition, DHBB significantly improved the gut barrier function through up-regulating the levels of tight junction proteins and mucins. Furthermore, DHBB dramatically ameliorated colonic immune-inflammation state, which was related to the decrease of colonic pro-inflammatory cytokines and immunoglobulin through blocking TLR4/MyD88/NF-κB signal pathway.
CONCLUSION: These results demonstrated that DHBB exerted a significant protective effect on DSS-induced experimental UC, at least partly through suppressing immune-inflammatory response and maintaining gut barrier function.
Copyright © 2021. Published by Elsevier GmbH.

Entities:  

Keywords:  Dihydroberberine; Gut barrier function; Inflammatory cytokines; TLR4/MyD88/NF-κB; Ulcerative colitis

Year:  2021        PMID: 34253428     DOI: 10.1016/j.phymed.2021.153631

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  6 in total

1.  Network Pharmacology-Based Strategy to Identify the Pharmacological Mechanisms of Pulsatilla Decoction against Crohn's Disease.

Authors:  Jinguo Liu; Lu Zhang; Zhaojun Wang; Shanshan Chen; Shuyan Feng; Yujin He; Shuo Zhang
Journal:  Front Pharmacol       Date:  2022-04-05       Impact factor: 5.988

Review 2.  Phytochemicals targeting Toll-like receptors 4 (TLR4) in inflammatory bowel disease.

Authors:  Wenbin Dai; Longhai Long; Xiaoqiang Wang; Sen Li; Houping Xu
Journal:  Chin Med       Date:  2022-04-28       Impact factor: 4.546

3.  Active Ingredients and Potential Mechanisms of the Gan Jiang-Huang Qin-Huang Lian-Ren Shen Decoction against Ulcerative Colitis: A Network Pharmacology and Molecular Docking-Based Study.

Authors:  Ce Zhou; Hang Zhou; Furong Zhang; Liangliang Hao; Jing Guo
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-08       Impact factor: 2.629

Review 4.  Gut Microbiota: The Potential Key Target of TCM's Therapeutic Effect of Treating Different Diseases Using the Same Method-UC and T2DM as Examples.

Authors:  Boxun Zhang; Ke Liu; Haoyu Yang; Zishan Jin; Qiyou Ding; Linhua Zhao
Journal:  Front Cell Infect Microbiol       Date:  2022-03-30       Impact factor: 5.293

5.  Pharmacological effects of berberine on models of ulcerative colitis: A meta-analysis and systematic review of animal studies.

Authors:  Shuangyuan Hu; Pengfei Wei; Wei Li; Qingsong Liu; Shuanglan Chen; Caiyu Hu; Xiaochuan Guo; Xiao Ma; Jinhao Zeng; Yi Zhang
Journal:  Front Pharmacol       Date:  2022-09-06       Impact factor: 5.988

Review 6.  Current Advances in Coptidis Rhizoma for Gastrointestinal and Other Cancers.

Authors:  Luying He; Zhangfeng Zhong; Man Chen; Qilian Liang; Yitao Wang; Wen Tan
Journal:  Front Pharmacol       Date:  2022-01-03       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.